Carbidopa/Entacapone/Levodopa

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Tridentify are delighted to announce that Intrance Medical Systems Inc. now have signed a LOI purchase commitment of $ 300 000. Their Tridentify safeguarding solution will be used for the 'logistic journey' of the drug component for clinical trials in at least Europe and the US for patients with Parkinson diseases in advanced stage. The clinical development program for US registration has recently been initiated, with a larger more extensive study planned for late 2024. "Intrance Medical Systems is focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson's disease. The product, Lecigon, is successfully marketed and available across Europe (by Britannia Pharmaceuticals). Intrance Medical plans to bring this innovative system to the US, Canada, Japan, Taiwan and LATAM. The US clinical development program includes key studies where accurate data to the FDA is paramount. Since Lecigon requires an unbroken cold supply chain and whose properties can change if improperly handled, we have found that Tridentify has a unique solution with monitoring and continuous calculation of remaining shelf life. We're excited about our collaboration and anticipate extending our partnership in the future," says Patrick Shea, CEO at Intrance Medical Systems Inc. " Tridentify is excited about the next steps with Intrance Medical Inc. Together with Intrance we want to ensure high quality standards in their important development of a new Parkinson treatment. We are proud to be able to safeguard the shipments for the clinical trials in Europe and in the US, as well as to support the important safety for patients with severe diseases," says Ann-Christine Jungmar, CEO at Tridentify. For further information, kindly contact: Ann-Christine Jungmar, CEO Tridentify +46 708 71 46 76 [email protected] This information was brought to you by Cision The following files are available for download:

NEW YORK--( BUSINESS WIRE )--Intrance Medical Systems, Inc., a biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease, today announced the appointment of Ashley Prange to the position of Vice President of Business Development. “ We are pleased to welcome Ashley to Intrance at an important time when we are making continued progress with our lead asset for advanced Parkinson’s disease, preparing to initiate our pivotal clinical trial, and successfully implementing other key strategic initiatives,” said Patrick Shea, Chief Executive Officer of Intrance Medical Systems. “ Ashley is a wonderful addition to our team. Her experience leading commercial and business development activities within the pharmaceutical industry will be tremendously valuable as we strengthen our focus on strategic partnerships in the U.S. and other select countries to ensure our innovative drug-device therapy reaches as many patients with advanced Parkinson’s disease as possible.” In her role at Intrance Medical Systems, Ms. Prange will be responsible for building and implementing the company’s strategic partnering initiatives for the U.S., Japan, Taiwan, Canada, and South America. Specifically, she will be instrumental in helping Intrance initiate ex-U.S. out-licensing activities as well as explore commercial collaborations in the U.S. for its lead clinical product, known as Lecigon® in Europe, to ensure optimal geographic coverage. Intrance Medical Systems formally established its U.S. operations in April 2021 with the goal to bring its novel treatment approach for late-stage Parkinson’s disease to markets where the company owns and controls all intellectual property and commercial rights. These markets include the U.S., Canada, Mexico, South America, Japan and Taiwan. In the U.S., Intrance has submitted an Initial New Drug (IND) application to the U.S. Food and Drug Administration (FDA) under the 505(b)(2) pathway. “ As we continue to see impressive physician and patient adoption of Lecigon across approximately 20 countries in Europe by the work of STADA/Britannia, we are steadfast in our mission to bring our novel drug-device system to the U.S. and other key markets to help improve patient quality of life and treatment outcomes,” added Ulf Rosén, Co-founder and Chairman of the Board of Intrance Medical Systems. Ms. Prange has strong commercial and business development experience across multiple therapeutic areas, including neurology and Central Nervous System (CNS) diseases. She formerly served as Director of Business Development at Azurity Pharmaceuticals, where she led the licensing and product acquisition team responsible for identifying strategic business opportunities. Prior to Azurity, she was Director of Business Development at Arbor Pharmaceuticals (acquired by Azurity in 2021) working closely with the board and management team to spearhead high-priority strategic corporate transactions. Ms. Prange earned her bachelor’s degree in Journalism specializing in Advertising and Sports Marketing from the University of North Carolina Chapel Hill. About Intrance Medical Systems Intrance Medical Systems, Inc., is a private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, South America, Japan and Taiwan. Intrance’s lead product, known as Lecigon® in the European market, is a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The company is planning to advance its U.S. clinical development program in this target indication and has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) under the 505(b)(2) pathway. For more information, visit intrancemedical.com .​